ArticleInternational journal of hematology2023

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

Ana C Oliveira et al.PubMed ↗Publisher ↗

No numbers read from the abstract.